These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 23565554)

  • 21. Treatment Response After Unusual Low Dose Sorafenib: Diagnosis with Perfusion CT and Follow-up in a Patient with Recurrent Hepatocellular Carcinoma.
    Sacco R; Faggioni L; Bargellini I; Romano A; Bertini M; Ginanni B; Battaglia V; Bertoni M; Bozzi E; Federici G; Metrangolo S; Parisi G; Neri E; Sodini E; Tumino E; Bresci G; Bartolozzi C
    J Gastrointest Cancer; 2012 Sep; 43 Suppl 1():S234-8. PubMed ID: 22752423
    [No Abstract]   [Full Text] [Related]  

  • 22. Decrease in tumor enhancement on contrast-enhanced CT is associated with improved survival in patients with hepatocellular carcinoma treated with Sorafenib.
    Patchett N; Furlan A; Marsh JW
    Jpn J Clin Oncol; 2016 Sep; 46(9):839-44. PubMed ID: 27317737
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Decade in review-hepatocellular carcinoma: HCC-subtypes, stratification and sorafenib.
    Gores GJ
    Nat Rev Gastroenterol Hepatol; 2014 Nov; 11(11):645-7. PubMed ID: 25245016
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sorafenib: the gold standard therapy in advanced hepatocellular carcinoma and beyond.
    Gadaleta-Caldarola G; Divella R; Mazzocca A; Infusino S; Ferraro E; Filippelli G; Daniele A; Sabbà C; Abbate I; Brandi M
    Future Oncol; 2015; 11(16):2263-6. PubMed ID: 26260805
    [No Abstract]   [Full Text] [Related]  

  • 25. Quantitative therapy response assessment by volumetric iodine-uptake measurement: initial experience in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Dai X; Schlemmer HP; Schmidt B; Höh K; Xu K; Ganten TM; Ganten MK
    Eur J Radiol; 2013 Feb; 82(2):327-34. PubMed ID: 23246016
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of sorafenib for hepatocellular carcinoma by contrast-enhanced ultrasonography: a pilot study.
    Shiozawa K; Watanabe M; Kikuchi Y; Kudo T; Maruyama K; Sumino Y
    World J Gastroenterol; 2012 Oct; 18(40):5753-8. PubMed ID: 23155317
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advanced Hepatocellular Carcinoma: Pretreatment Contrast-enhanced CT Texture Parameters as Predictive Biomarkers of Survival in Patients Treated with Sorafenib.
    Mulé S; Thiefin G; Costentin C; Durot C; Rahmouni A; Luciani A; Hoeffel C
    Radiology; 2018 Aug; 288(2):445-455. PubMed ID: 29584597
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of response to sorafenib in advanced hepatocellular carcinoma using perfusion computed tomography: results of a pilot study.
    Sacco R; Faggioni L; Bargellini I; Ginanni B; Battaglia V; Romano A; Bertini M; Bresci G; Bartolozzi C
    Dig Liver Dis; 2013 Sep; 45(9):776-81. PubMed ID: 23578581
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exceptional serological and radiological response to sorafenib in 2 patients with advanced hepatocellular carcinoma and chronic hepatitis C viral infection: case report and review of the literature.
    Atkin C; Earwaker P; Pallan A; Shetty S; Punia P; Ma YT
    BMC Gastroenterol; 2017 Feb; 17(1):30. PubMed ID: 28193171
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Treatment of advanced hepatocellular carcinoma].
    Kudo M
    Nihon Shokakibyo Gakkai Zasshi; 2012 Aug; 109(8):1327-34. PubMed ID: 22863955
    [No Abstract]   [Full Text] [Related]  

  • 31. The role of sorafenib in hepatocellular carcinoma.
    Gholam P
    Clin Adv Hematol Oncol; 2015 Apr; 13(4):232-4. PubMed ID: 26352581
    [No Abstract]   [Full Text] [Related]  

  • 32. Complete Response to Full-Dose Sorafenib Treatment in an Elderly HCC Patient: a Case Report.
    de Stefano G; Iodice V; Farella N
    J Gastrointest Cancer; 2015 Dec; 46(4):430-3. PubMed ID: 25894635
    [No Abstract]   [Full Text] [Related]  

  • 33. Treatment of advanced hepatocellular carcinoma: beyond sorafenib.
    Meyer T
    Lancet Gastroenterol Hepatol; 2018 Apr; 3(4):218-220. PubMed ID: 29533189
    [No Abstract]   [Full Text] [Related]  

  • 34. Characteristics of long-term survivors following sorafenib treatment for advanced hepatocellular carcinoma: report of a workshop at the 50th Annual Meeting of the Liver Cancer Study Group of Japan.
    Tanaka K; Shimada M; Kudo M
    Oncology; 2014; 87 Suppl 1():104-9. PubMed ID: 25427741
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Partial Response and Cardiovascular Recovery after Sorafenib Dose Reduction in a Multinodular HCC Patient.
    Sacco R; Bargellini I; Ginanni B; Bertini M; Bozzi E; Altomare E; Battaglia V; Romano A; Tumino E; Di Biase M; Bresci G; Bartolozzi C
    J Gastrointest Cancer; 2012 Sep; 43 Suppl 1():S89-92. PubMed ID: 21975578
    [No Abstract]   [Full Text] [Related]  

  • 36. A case of reversible cardiomyopathy associated with sorafenib in advanced hepatocellular carcinoma.
    Park H; Han SH; Kang H; Park K
    Int J Cardiol; 2012 Sep; 160(1):e10-1. PubMed ID: 22289299
    [No Abstract]   [Full Text] [Related]  

  • 37. Complete Response to the Combination of Pembrolizumab and Sorafenib for Metastatic Hepatocellular Carcinoma: A Case Report.
    Chen SC; Chao Y; Yang MH
    Am J Gastroenterol; 2017 Apr; 112(4):659-660. PubMed ID: 28381841
    [No Abstract]   [Full Text] [Related]  

  • 38. Severe adverse skin reaction and desensitization to sorafenib.
    Linauskiene K; Malinauskiene L; Vitkauskaite E; Chomiciene A; Blaziene A
    Ann Allergy Asthma Immunol; 2016 Aug; 117(2):209-10. PubMed ID: 27372655
    [No Abstract]   [Full Text] [Related]  

  • 39. Letter: The antiviral activity of sorafenib in patients with hepatitis C-related hepatocellular carcinoma.
    Ji F; Li Z
    Aliment Pharmacol Ther; 2013 Feb; 37(3):372-3. PubMed ID: 23281732
    [No Abstract]   [Full Text] [Related]  

  • 40. [Metastatic adrenal necrosis under sorafenib treatment for hepatocellular carcinoma].
    Fabries P; Pauleau G; Brardjanian S; Artéaga C; Guisset M; Coton T
    Presse Med; 2013 Feb; 42(2):235-7. PubMed ID: 22425476
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.